A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

Running, not enrolling · Phase 3

Conditions studied: Hemophilia

In brief

This is a multicenter, multinational, open-label, one-way cross-over, Phase 3, single-arm study for treatment of hemophilia. The purpose of this study is to measure the frequency of treated bleeding episodes with fitusiran in male adult and adolescent (≥12 years old) participants with hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX who have switched from their prior standard of care treatment. The total study duration will be up to approximately 50 months (200 weeks, 1 study month is equivalent to 4 weeks) and will include: * A screening period up to approximately 60 days, * A standard of care (SOC) period of approximately 6 study months (24 weeks), * A fitusiran treatment period of approximately 36 study months (144 weeks), * An antithrombin (AT) follow-up period of approximately 6 study months (24 weeks) but may be shorter or longer depending on individual participants AT recovery. The frequency for telephone visits will be approximately every 2 weeks. For site visits the frequency will be approximately every 8 weeks during the SOC period and approximately every 4 weeks during the fitusiran treatment period. If applicable and if allowed by local regulation, home and/or remote visits may be conducted during the study

Key facts

Study ID: NCT05662319
Run by: Sanofi
People needed: 91
Starts: 2023-02-01
Expected to finish: 2029-01-25
Last updated by the study team: 2026-02-04

Who can join

Age: 12 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

Diagnosis of severe congenital hemophilia A or B (FVIII <1% or FIX level ≤2%) as evidenced by a central laboratory measurement at screening or documented medical record evidence.
For participants currently not on prophylaxis (CFC or BPA on-demand): A minimum of 4 bleeding episodes requiring BPA (inhibitor participants) or CFC (non-inhibitor participants) treatment within the last 6 months prior to screening.
Willing and able to comply with the study requirements and to provide written informed consent and assent in the case of participants under the age of legal consent, per local and national requirements

You may not qualify if…

Known co-existing bleeding disorders other than congenital hemophilia A or B
History of arterial or venous thromboembolism, not associated with an indwelling venous access
History of intolerance to SC injection(s).
Current participation in immune tolerance induction therapy (ITI)
Prior gene therapy
Current or prior participation in a fitusiran trial
Current or prior participation in a gene therapy trial
Received an investigational drug or device within 30 days prior to the screening visit or within 5 half-lives of the investigational drug (or device) prior to the screening visit, whichever is longer
Presence of clinically significant liver disease AT activity <60% at Screening
Co-existing thrombophilic disorder
Hepatitis C virus antibody positive, except participants who have negative Hepatitis C viral load and no evidence of cirrhosis
Presence of acute hepatitis, ie, hepatitis A, hepatitis E.
Presence of acute or chronic hepatitis B infection
Known to be HIV positive with CD4 count <200 cells/μL.
Reduced renal function The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it is running

Center for Inherited Blood Disorders (CIBD) Site Number : 8400012 — Orange, California, United States
M Health Fairview University of Minnesota Medical Center - West Bank- Site Number : 8400016 — Minneapolis, Minnesota, United States
Hackensack University Site Number : 8400009 — Hackensack, New Jersey, United States
Northwell Health Hemostasis and Thrombosis Center Site Number : 8400015 — New Hyde Park, New York, United States
University Hospitals of Cleveland Site Number : 8400001 — Cleveland, Ohio, United States
UPMC Children's Hospital of Pittsburgh-4401 Penn Ave Site Number : 8400017 — Pittsburgh, Pennsylvania, United States
Children's Medical Center Dallas- Site Number : 8400018 — Dallas, Texas, United States
Gulf States Hemophilia and Thrombophilia Center- Site Number : 8400002 — Houston, Texas, United States
Investigational Site Number : 1240001 — Hamilton, Ontario, Canada
Investigational Site Number : 1240002 — Hamilton, Ontario, Canada
Investigational Site Number : 1240004 — Toronto, Ontario, Canada
Investigational Site Number : 1560003 — Beijing, China
Investigational Site Number : 1560001 — Guangzhou, China
Investigational Site Number : 1560002 — Jinan, China
Investigational Site Number : 2500003 — Le Kremlin-Bicêtre, France
Investigational Site Number : 2500002 — Lille, France
Investigational Site Number : 2500001 — Paris, France
Investigational Site Number : 2760001 — Berlin, Germany
Investigational Site Number : 2760002 — Hamburg, Germany
Investigational Site Number : 3000001 — Athens, Greece
Investigational Site Number : 3000002 — Athens, Greece
Investigational Site Number : 3560004 — Bangalore, India
Investigational Site Number : 3560007 — Bhubaneswar, India
Investigational Site Number : 3560001 — Pune-411011, India
Investigational Site Number : 3560006 — Punjab, India

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.